This method quantifies dissociation kinetics in mixtures of ligands, suggesting improved drug development efficiency.
Ligand-observed NMR is a key tool for detecting weak protein-ligand interactions, but translating binding signals into meaningful affinity measurements remains difficult, limiting the ability to rank and prioritize compounds in drug development campaigns. Here, we propose a conceptual shift by using ligand-observed 19F NMR R1ρ relaxation dispersion to screen compounds by dissociation kinetics rather than binding thermodynamics. The first-order nature of ligand dissociation enables direct measurement in complex mixtures, and we have successfully extracted rate constants (3,500–65,000 s-1) from mixtures of up to 30 compounds across three protein targets. This kinetic approach delivers medicinal chemists a simple, actionable parameter, typically in under 30 minutes per compound. With open-source and user-friendly analysis software developed, we anticipate this approach will accelerate drug development campaigns by facilitating the screening, characterisation, and ranking of compound libraries.
No takes yet. Share an insight, caveat, or question.
Hazlett et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: